Merck and Moderna’s Cancer Vaccine Combination Meets Phase III Endpoints in Melanoma
Merck and Moderna reported that the randomized Phase III INTerpath-001 trial met its primary recurrence-free-survival (RFS) endpoint and key secondary distant-metastasis-free-survival (DMFS) endpoint at a prespecified interim analysis. The study compares individualized neoantigen therapy…
